The Hyperhidrosis Disease Severity Measure-Axillary: Conceptualization and Development of Item Content
dc.contributor.author | Kirsch, BM | |
dc.contributor.author | Burke, L | |
dc.contributor.author | Hobart, J | |
dc.contributor.author | Angulo, D | |
dc.contributor.author | Walker, PS | |
dc.date.accessioned | 2018-03-28T08:54:26Z | |
dc.date.issued | 2018-07 | |
dc.identifier.issn | 1545-9616 | |
dc.identifier.uri | http://hdl.handle.net/10026.1/11190 | |
dc.description | Content published in the Journal of Drugs in Dermatology (JDD) — which is supplied either in print or digital form, including but not limited to: the printed journal (including supplements); pre-reprints; reprints; e-prints; online articles, portion of journal or entire issue; digital proofs (pdf or any other format); and any other forms — may NOT be copied, scanned, digitally captured, modified, reproduced, uploaded, posted, republished, transmitted, stored, archived, or distributed in any way unless such use is specifically permitted via a signed, duly authorized agreement. No part of JDD content may be reproduced or transmitted in any form, by any means now known or hereafter developed, without prior written permission of the publisher. | |
dc.description.abstract |
INTRODUCTION: Patients with primary axillary hyperhidrosis (AHH) suffer from a variety of symptoms. Improved patient-reported outcome (PRO) measures are needed to better assess and categorize the severity of AHH symptoms experienced by patients because the widely used Hyperhidrosis Disease Severity Scale (HDSS) is a single-item measure that cannot capture the broad scope of disease impact. METHODS: The Hyperhidrosis Disease Severity Measure-Axillary (HDSM-Ax) was developed for determining the severity of excessive sweating in patients with primary focal AHH based on face-to-face concept elicitation interviews with 58 AHH patients, a literature review, and expert clinical input. Two waves of face-to-face cognitive interviews (n=26 and n=27) were conducted to evaluate HDSM-Ax clarity and relevance. Additional interviews (n=5) were conducted to confirm content. Adding Rasch Measurement Theory (RMT) analyses allowed for an iterative streamlined approach to documenting content validity and other cross-sectional measurement properties of the new HDSM-Ax measurement. RESULTS: The 11-item HDSM-Ax PRO scale (0-4 scale per item; 0-44 total scale) represents an AHH symptom range of 0 (no sweating) to 44 (worst possible sweating). Content validity of the HDSM-Ax was documented by showing that chronologically-grouped interviews demonstrated saturation in AHH symptom severity concepts. Cognitive debriefing interviews provided evidence that item content is complete, comprehensible, meaningful, and relevant. RMT-based exploration indicated that targeting of the HDSM-Ax was adequate, suggesting good matching between items and persons; item fit was adequate, suggesting a clinically cohesive scale; and items appeared to be stable between subgroups, thereby supporting a summary score. CONCLUSIONS: The HDSM-Ax is a well-developed measure of AHH severity based on patient-reported signs and symptoms. It is a superior measure to the HDSS and can be used in clinical research and clinical practice to quantify changes in symptom severity in response to treatment. J Drugs Dermatol. 2018;17(7):707-714. | |
dc.format.extent | 707-714 | |
dc.format.medium | ||
dc.language | eng | |
dc.language.iso | en | |
dc.publisher | Strategic Communication in Dermatology | |
dc.subject | Adult | |
dc.subject | Axilla | |
dc.subject | Cross-Sectional Studies | |
dc.subject | Female | |
dc.subject | Humans | |
dc.subject | Hyperhidrosis | |
dc.subject | Male | |
dc.subject | Middle Aged | |
dc.subject | Patient Reported Outcome Measures | |
dc.subject | Quality of Life | |
dc.subject | Severity of Illness Index | |
dc.subject | Telephone | |
dc.subject | Young Adult | |
dc.title | The Hyperhidrosis Disease Severity Measure-Axillary: Conceptualization and Development of Item Content | |
dc.type | journal-article | |
dc.type | Comparative Study | |
dc.type | Journal Article | |
dc.type | Validation Study | |
plymouth.author-url | https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000453940700001&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=11bb513d99f797142bcfeffcc58ea008 | |
plymouth.issue | 7 | |
plymouth.volume | 17 | |
plymouth.publication-status | Published | |
plymouth.journal | Journal of Drugs in Dermatology | |
plymouth.organisational-group | /Plymouth | |
plymouth.organisational-group | /Plymouth/Faculty of Health | |
plymouth.organisational-group | /Plymouth/Faculty of Health/Peninsula Medical School | |
plymouth.organisational-group | /Plymouth/REF 2021 Researchers by UoA | |
plymouth.organisational-group | /Plymouth/REF 2021 Researchers by UoA/UoA03 Allied Health Professions, Dentistry, Nursing and Pharmacy | |
plymouth.organisational-group | /Plymouth/Research Groups | |
plymouth.organisational-group | /Plymouth/Research Groups/Institute of Translational and Stratified Medicine (ITSMED) | |
plymouth.organisational-group | /Plymouth/Research Groups/Institute of Translational and Stratified Medicine (ITSMED)/CCT&PS | |
plymouth.organisational-group | /Plymouth/Users by role | |
plymouth.organisational-group | /Plymouth/Users by role/Academics | |
dc.publisher.place | United States | |
dcterms.dateAccepted | 2018-02-14 | |
dc.rights.embargodate | 9999-12-31 | |
dc.rights.embargoperiod | Not known | |
rioxxterms.licenseref.uri | http://www.rioxx.net/licenses/all-rights-reserved | |
rioxxterms.licenseref.startdate | 2018-07 | |
rioxxterms.type | Journal Article/Review |